Agilent Technologies, Inc.

NYSE:A

Medical - Diagnostics & Research

Healthcare
$177.33 +2.44%

+$3.04 today

Market cap
$50.00B
Beta
1.26
P/E (TTM)
25.5
EPS (TTM)
$5.00
Dividend yield
0.59%
52W Low $108.35High $160.27

Volume 2.48M

Average 2.24M

A Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Agilent Technologies, Inc.NYSE: A

Depreciation & Amortization · Q3 FY2026 · quarter ended Jul 2026

Depreciation & amortization declines year over year

Q3 FY2026 depreciation & amortization of $66M fell 8.3% year over year, behind the -5.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.5% from the prior quarter. Over 3 fiscal years it compounded at -3.1% a year.

Context

  • Depreciation & amortization amounted to 4.1% of revenue in FY2025, up 0.2 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -8.3% toward the trailing-twelve-month pace of -5.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJul 2026
$66M-1.5% QoQ
Last fiscal yearOct 2025
$288M+12.1% YoY
LTMJul 2026
$271M-5.2% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.3%——
1 year+12.1%——
3-year CAGR-3.1%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
288M USD
Year-over-year change
+12.1%
4-year CAGR
-2.7%

Depreciation & Amortization vs competitors

How A compares with its peers on the latest reported figures

  • A's LTM Jul 2026 depreciation & amortization of $271M is the 5th largest of the 9 companies compared; the peer median is $321.17M.
  • Its year-over-year change of -5.2% is the 7th highest of 9, against a peer median of +7.2%.
  • Depreciation & amortization amounts to 3.7% of revenue for A, versus a peer median of 7.0%.
A Competitors Peer median
Depreciation & Amortization for A and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TMOThermo Fisher Scientific Inc.LTM Sep 2026$3.11B +11.2%-6.3%6.6%
DHRDanaher CorporationLTM Sep 2026$1.91B -21.1%+4.7%7.5%
WATWaters CorporationLTM Jul 2026$613.22M +211.1%+16.5%13.2%
RVTYRevvity, Inc.LTM Jul 2026$412.24M -0.2%-1.7%14.2%
AAgilent Technologies, Inc.LTM Jul 2026$271M -5.2%-3.1%3.7%
BRKRBruker CorporationLTM Jun 2026$230.1M +9.4%+35.4%6.6%
QGENQiagen N.V.LTM Jun 2026$202.13M +7.0%-2.4%9.6%
MTDMettler-Toledo International Inc.LTM Jun 2026$131M +7.3%+3.6%3.2%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$127.6M -23.5%+6.4%4.9%
Peer median (excluding A) $321.17M+7.2%+4.1%7.0%

Competitors are the stored peer set for A. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Oct 2021
FY2022
Oct 2022
FY2023
Oct 2023
FY2024
Oct 2024
FY2025
Oct 2025
Net Income1.21B1.25B1.24B1.29B434M
Depreciation & Amortization321M317M271M257M288M
Deferred Income Tax14M8M(56M)(64M)(130M)
Stock-Based Compensation110M125M111M129M128M
Change in Working Capital(102M)(478M)(116M)83M(58M)
Accounts Receivables(128M)(321M)132M7M(149M)
Inventory(136M)(248M)(33M)34M45M
Accounts Payables64M121M(171M)103M16M
Other Working Capital98M(30M)(44M)(61M)30M
Other Non-Cash Items(68M)86M322M57M897M
Operating Cash Flow1.49B1.31B1.77B1.75B1.56B
Capital Expenditures(189M)(291M)(298M)(378M)(407M)
Acquisitions (Net)(546M)(52M)(1M)(862M)4M
Purchases of Investments(22M)(13M)(8M)(5M)0
Sales of Investments12M22M5M08M
Other Investing Activities(4M)(4M)(8M)(13M)(199M)
Investing Cash Flow(749M)(338M)(310M)(1.26B)(394M)
Debt Repayment356M26M(35M)637M(41M)
Common Stock Issued000072M
Common Stock Repurchased(788M)(1.14B)(575M)(1.15B)(425M)
Dividends Paid(236M)(250M)(265M)(274M)(282M)
Other Financing Activities(28M)58M(55M)35M(39M)
Financing Cash Flow(696M)(1.37B)(930M)(752M)(715M)
Effect of Forex Changes3M(36M)5M(2M)9M
Net Change in Cash43M(434M)537M(261M)459M
Free Cash Flow1.3B1.02B1.47B1.37B1.15B

Agilent Technologies, Inc.

NYSE:A

Intrinsic Alpha fair value

Locked

Current Price

$177.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.